Kowa Pharmaceuticals America, Inc. Sustainability Profile
Kowa Pharmaceuticals America, Inc., a subsidiary of Kowa Company, Ltd., is a prominent player in the pharmaceutical industry, headquartered in the United States. Established in 2001, the company has made significant strides in developing innovative therapies, particularly in the areas of cardiovascular health, diabetes management, and ophthalmology. Kowa Pharmaceuticals is renowned for its unique product offerings, including prescription medications that address critical health issues. The company’s commitment to research and development has positioned it as a leader in the market, with notable achievements in bringing effective treatments to patients. With a strong operational presence across the US, Kowa Pharmaceuticals continues to enhance its reputation through a focus on quality and patient-centric solutions.
DitchCarbon Score
How does Kowa Pharmaceuticals America, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kowa Pharmaceuticals America, Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kowa Pharmaceuticals America, Inc.'s reported carbon emissions
Kowa Pharmaceuticals America, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary and may inherit emissions data from its parent organisation, but no specific details have been provided regarding this cascade. In terms of climate commitments, Kowa Pharmaceuticals America, Inc. has not outlined any specific reduction targets or initiatives, such as those associated with the Science Based Targets initiative (SBTi) or other industry-standard climate pledges. The lack of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As a subsidiary, Kowa Pharmaceuticals America, Inc. may align its climate efforts with broader corporate family initiatives, but specific details on these relationships or inherited data are not available. Overall, the company appears to be in a position to enhance its climate commitments and emissions reporting in the future.
How Carbon Intensive is Kowa Pharmaceuticals America, Inc.'s Industry?
How Carbon Intensive is Kowa Pharmaceuticals America, Inc.'s Location?
Kowa Pharmaceuticals America, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Kowa Pharmaceuticals America, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
